These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26243735)

  • 121. The Use of Apremilast to Treat Psoriasis During Deployment.
    Rosenberg A; Meyerle J
    Mil Med; 2017 Jul; 182(7):1628-1631. PubMed ID: 28810954
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial.
    Konishi R; Tanaka R; Inoue S; Ichimura Y; Nomura T; Okiyama N
    J Dermatol; 2022 Jan; 49(1):118-123. PubMed ID: 34605053
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Kang Q; Chen JS; Yang H
    Front Immunol; 2022; 13():1021537. PubMed ID: 36300119
    [TBL] [Abstract][Full Text] [Related]  

  • 124. The Use of Apremilast in Psoriasis: A Delphi Study.
    Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
    Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
    Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
    Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Apremilast (otezla) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 May; 56(1443):41-2. PubMed ID: 24869713
    [No Abstract]   [Full Text] [Related]  

  • 128. Management of Common Side Effects of Apremilast.
    Langley A; Beecker J
    J Cutan Med Surg; 2018; 22(4):415-421. PubMed ID: 29290125
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
    Okazaki S; Osawa R; Nakajima H; Nakajima K; Sano S
    J Dermatol; 2019 Jun; 46(6):544-547. PubMed ID: 30957901
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Multidisciplinary Management of the Adverse Effects of Apremilast.
    Daudén Tello E; Alonso Suárez J; Beltrán Catalán E; Blasco Maldonado C; Herrero Manso MC; Jiménez Morales A; Marín-Jiménez I; Martín-Arranz MD; García-Merino A; Porta Etessam J; Rodríguez-Sagrado MA; Rosas Gómez de Salazar J; Trujillo Martín E; Salgado-Boquete L
    Actas Dermosifiliogr (Engl Ed); 2021 Feb; 112(2):134-141. PubMed ID: 32910923
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 133. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
    Wegesser T; Coppi A; Harper T; Paris M; Minocherhomji S
    Regul Toxicol Pharmacol; 2021 Oct; 125():104985. PubMed ID: 34237378
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
    Huh KY; Choi Y; Nissel J; Palmisano M; Wang X; Liu L; Ramirez-Valle F; Lee H
    Clin Transl Sci; 2021 Jul; 14(4):1505-1511. PubMed ID: 33932093
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
    Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
    J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
    Melis D; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 Jul; 33(4):e13722. PubMed ID: 32475036
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
    Hsu SH; Tsai TF
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
    [No Abstract]   [Full Text] [Related]  

  • 140. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review.
    Ghamrawi RI; Ghiam N; Wu JJ
    J Dermatolog Treat; 2022 Feb; 33(1):94-99. PubMed ID: 32419531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.